biote Corp. (BTMD)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-06

Key Insights

Q1 2026 earnings announcement filed on May 6, 2026 for the quarter ended March 31, 2026, indicating timely financial reporting and adherence to SEC disclosure requirements.
Company maintains emerging growth company status, allowing potential benefits from scaled regulatory compliance and extended transition periods for accounting standards, which may reduce near-term compliance costs.
Press release details are furnished but not filed, limiting legal liability exposure under Section 18 of the Exchange Act and suggesting management is exercising cautious disclosure practices.

Current Report Filed: 2026-04-03

Key Insights

biote Corp. has filed an 8-K report disclosing the posting of its updated Investor Presentation on the company's website.
The Investor Presentation likely contains important information about the company's financial performance, business strategy, and other key developments.
Investors should review the Investor Presentation for any material updates or changes that could impact the company's outlook and investment thesis.

Insider Trading Filed: 2026-04-03

Key Insights

Robert Charles Peterson, the Chief Financial Officer of biote Corp., acquired 107,169 stock options on 2026-04-01 at an exercise price of $1.43 per share.
The options will vest over 36 months, with 25% vesting on 2027-04-01 and the remaining shares vesting monthly thereafter.
This insider transaction suggests that the CFO is confident in the company's future prospects and is aligning his interests with those of shareholders.

Insider Trading Filed: 2026-04-03

Key Insights

Bret Christensen, the CEO of biote Corp. (BTMD), acquired a new stock option grant of 441,653 shares of Class A common stock, vesting over 36 months.
The exercise price of the new option grant is $1.43 per share, which appears to be at the current market price based on the information provided.
Insider buying of this magnitude by the CEO is generally seen as a positive signal, indicating his confidence in the company's future performance.

Current Report Filed: 2026-03-11

Key Insights

biote Corp. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025, indicating the company's financial performance over the past year.
The company is an emerging growth company, which means it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies.
Investors should review the company's press release and financial statements to assess the company's financial condition, results of operations, and any material events or developments.

Current Report Filed: 2026-01-26

Key Insights

biote Corp. has initiated a voluntary recall of specific hormone pellet lots due to potential metal particulate matter contamination, which will result in a one-time charge of approximately $1.3M in the fourth quarter.
The recall is not expected to significantly impact biote's ability to supply pellets to its practitioner partners or their ability to serve patients, but the company may incur additional costs of around $1.0M in 2026 related to the recall.
The company does not believe its fourth quarter business was impacted beyond the inventory write-off, and it will provide more details on the financial impact when reporting its Q4 results.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.